Coronaviruses, such as HCoV 229E and HCoV OC43, were identified in the early 1960s. This coronavirus causes the most severe acute respiratory illnesses. SARS is a coronavirus that has been connected to a respiratory illness in the Middle East (MERS). The outbreak of Novel corona virus disease (COVID-19) was initially noticed in mid December, 2019,To improve the success rate of COVID-19treatment, several pharmacological approaches are proposed, and some clinical data are reviewed in the literature. Comorbid patients require many pharmacological therapies. Multiple medication use (polypharmacy) dramatically increases pharmacological adverse effects. As a result, diagnosis and treatment of drug-drug and disease-drug interactions are critical. When prescribing new drugs to COVID-19patients, clinicians should examine the likelihood of drug-drug and disease-drug interactions. Detecting drug-drug and disease-drug interactions of the medications utilized will thus be critical in the treatment of COVID-19. This article will concentrate on the drug-drug and disease-drug interactions of COVID-19 therapeutic medicines. Variations in the expression of a transporter are well recognized to result in changes in the PK/PD of the prescribed medication; hence, prescription medicine during inflammation may be a major contributor to inter-individual variability in drug efficacy and toxicity. It also highlighted the possibility of drug-drug and disease-drug interactions of the specified medicine in the treatment of COVID-19. It will aid in lowering risk in individuals with co-morbidities and providing better therapy with fewer adverse effects.
IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.
